Our mission is to translate scientific advances into new treatments for people with Amyotrophic Lateral Sclerosis (ALS) and Motor Neuron Disease (MND) as rapidly as possible.
To achieve our goal, NEALS functions as an academic research consortium, a contracted research organization, and a resource tool for ALS community. Learn more about our structure.
The NEALS consortium is committed to the principles of open scientific communication, peer review, full and open disclosure of potential conflicts of interest, and democratic governance of its organization and activities.
NEALS was founded in 1995 with 9 academic clinical centers in the New England area. With help from The ALS Association’s TREAT ALS Network, Muscular Dystrophy Association, and our generous donors, the NEALS membership has grown to over 100 research centers committed to performing research in ALS and MND.
Join us for the third installment of the NEALS webinar series on ALS drug development moderated by Dr. Richard Bedlack from the Duke ALS Clinic. This series will include talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, ethical considerations, the clinical trial site level overview, and the importance […]
Join us for the fourth installment of the NEALS webinar series on ALS drug development moderated by Dr. Richard Bedlack from the Duke ALS Clinic. This series will include talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, ethical considerations, the clinical trial site level overview, and the importance […]
Please join us for a conversation about the results of this trial and the next steps for AMX0035. Register now!
Dr. James Berry (primary investigator) will review the importance of biomarkers and the REFINE-ALS study, provide a study status update, discuss recent changes to the study, including the option for remote study visits. We hope you will join us to learn more about REFINE-ALS and how to get involved.
Dr. Merit Cudkowicz (Sean M. Healey & AMG Center for ALS at Mass General Hospital) will review the ALS clinical trial pipeline and answers questions about the current state of clinical research.
Join us for the fifth installment of the NEALS webinar series on ALS drug development moderated by Dr. Jinsy Andrews from Columbia University. This series will include talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, ethical considerations, the clinical trial site level overview, and the importance of patient […]
Dr. Nathan Crone (Johns Hopkins University) discusses the rationale for using brain-computer interfaces to support communication in people with severe motor impairments and describes two clinical trials of implantable brain-computer interfaces at Johns Hopkins.
Join Dr. Steven Zeiler, Dr. Terri Thompson and Ed Rapp on July 13th to hear more about the newly launched ALS Companion app and the Answer ALS data portal. Answer ALS is creating a hub of ALS knowledge and resources to help propel the research field forward. Find out how you can help.
Join us for the fifth installment of the NEALS webinar series on ALS drug development moderated by Dr. Richard Bedlack from Duke ALS Clinic. This series will include talks on the preclinical development of potential therapies, the regulatory pathway, the science of trials, ethical considerations, the clinical trial site level overview, and the importance of […]
Please join Dr. Merit Cudkowicz and Dr. Sabrina Paganoni for a conversation about recent updates on AMX0035 (sodium phenylbutyrate/taurursodiol) and to review details of the Phase 3 PHOENIX Study (Study A35-004). Register here.
Please join us to learn about COURAGE-ALS, a global phase 3 trial of reldesemtiv currently enrolling participants.
Please join us on February 24th for a webinar to learn about a new Phase 2a trial of Oral LAM-002A capsules for individuals with C9ORF72 positive ALS.